Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    B7471006
Previous Study | Return to List | Next Study

Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03835975
Recruitment Status : Recruiting
First Posted : February 11, 2019
Last Update Posted : February 26, 2019
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:
This Phase 3 will describe the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine formulation in adults 65 years of age or older with prior pneumococcal vaccination

Condition or disease Intervention/treatment Phase
Pneumococcal Disease Biological: 13vPnC Biological: PPSV23 Biological: 20vPnC Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 875 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION
Actual Study Start Date : February 12, 2019
Estimated Primary Completion Date : December 30, 2019
Estimated Study Completion Date : December 30, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: 13vPnC
Pneumococcal conjugate vaccine
Biological: 13vPnC
Pneumococcal conjugate vaccine

Active Comparator: PPSV23
Pneumococcal polysaccharide vaccine
Biological: PPSV23
Pneumococcal polysaccharide vaccine

Experimental: 20vPnC
Pneumococcal conjugate vaccine
Biological: 20vPnC
Pneumococcal conjugate vaccine




Primary Outcome Measures :
  1. Percentage of subjects reporting prompted local reactions (redness, swelling, and pain at the injection site) within 10 days after vaccination [ Time Frame: Day 10 ]
    Prompted local reactions after vaccination.

  2. Percentage of subjects reporting prompted systemic events (fever, headache, fatigue, muscle pain, and joint pain) within 7 days after vaccination [ Time Frame: Day 7 ]
    Prompted systemic events after vaccination.

  3. Percentage of subjects reporting adverse events (AEs) within 1 month after vaccination [ Time Frame: 1 month after vaccination ]
    Adverse events occurring within 1 month after vaccination.

  4. Percentage of subjects reporting serious adverse events (SAEs) and newly diagnosed chronic medical conditions (NDCMCs) within 6 months after vaccination [ Time Frame: 6 months after vaccination ]
    SAEs and NDCMCs occurring within 6 months after vaccination.

  5. Pneumococcal serotype-specific OPA titers 1 month after vaccination [ Time Frame: 1 month after vaccination ]
    OPA titers 1 month after vaccination.


Secondary Outcome Measures :
  1. Fold rise in serotype-specific OPA titers from before to 1 month after vaccination [ Time Frame: 1 month after vaccination ]
    Fold rise in OPA titers 1 month after vaccination.

  2. ≥4-Fold rise in serotype-specific OPA titers from before to 1 month after vaccination [ Time Frame: 1 month after vaccination ]
    Subjects with ≥4-fold rise in OPA titers 1 month after vaccination.

  3. Serotype-specific OPA titers greater than or equal to the lower limit of quantitation (≥ LLOQ) 1 month after vaccination [ Time Frame: 1 month after vaccination ]
    Subjects with OPA titers ≥ LLOQ 1 month after vaccination.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria

  1. Male or female adults 65 years of age or greater.
  2. Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
  3. Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.
  4. Male or female adults who meet 1 of the following:

    1. Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
    2. Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
    3. Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion Criteria

  1. Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
  2. History of microbiologically proven invasive disease caused by S pneumoniae.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03835975


Contacts
Layout table for location contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021 ClinicalTrials.gov_Inquiries@pfizer.com

Locations
Layout table for location information
United States, Alabama
Coastal Clinical Research Not yet recruiting
Mobile, Alabama, United States, 36608
United States, Arizona
East Valley Gastroenterology and Hepatology Associates Not yet recruiting
Chandler, Arizona, United States, 85224
The Pain Center of Arizona Not yet recruiting
Peoria, Arizona, United States, 85381
HOPE Research Institute (Administrative Site Only) Not yet recruiting
Phoenix, Arizona, United States, 85018
The Pain Center of Arizona Not yet recruiting
Phoenix, Arizona, United States, 85018
United States, California
Anaheim Clinical Trials, LLC Not yet recruiting
Anaheim, California, United States, 92801
Diablo Clinical Research, Inc. Not yet recruiting
Walnut Creek, California, United States, 94598
United States, Connecticut
Clinical Research Consulting, LLC Recruiting
Milford, Connecticut, United States, 06460
United States, Georgia
Clinical Research Atlanta Recruiting
Stockbridge, Georgia, United States, 30281
United States, Hawaii
East-West Medical Research Institute Not yet recruiting
Honolulu, Hawaii, United States, 96814
United States, Kansas
Heartland Research Associates, LLC Not yet recruiting
Wichita, Kansas, United States, 67207
United States, Nebraska
Meridian Clinical Research, LLC Recruiting
Norfolk, Nebraska, United States, 68701
United States, Ohio
Sterling Research Group, Ltd. Not yet recruiting
Cincinnati, Ohio, United States, 45246
Prestige Clinical Research Recruiting
Franklin, Ohio, United States, 45005
United States, South Carolina
Medical Research South, LLC Recruiting
Goose Creek, South Carolina, United States, 29445
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT03835975     History of Changes
Other Study ID Numbers: B7471006
2018-004278-91 ( EudraCT Number )
First Posted: February 11, 2019    Key Record Dates
Last Update Posted: February 26, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
URL: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumococcal Infections
Streptococcal Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Vaccines
Heptavalent Pneumococcal Conjugate Vaccine
Immunologic Factors
Physiological Effects of Drugs